What are the latest figures on the genomic biomarkers market’s size and projected CAGR?
The genomic biomarkers market size has grown rapidly in recent years. It will grow from $7.42 $ billion in 2024 to $8.72 $ billion in 2025 at a compound annual growth rate (CAGR) of 17.4%. The growth in the historic period can be attributed to the rising emphasis on various genetic testing activities, growing cases of chronic diseases, growing emphasis on precision medicine initiatives, growing adoption of companion diagnostics, and rising number of patients with neurological diseases.
The genomic biomarkers market size is expected to see rapid growth in the next few years. It will grow to $16.51 $ billion in 2029 at a compound annual growth rate (CAGR) of 17.3%. The growth in the forecast period can be attributed to the increasing number of ovarian and gastric cancer cases, growing acceptance and awareness of genetic testing, increasing use of genomic biomarkers in cancer diagnosis and treatment, increasing number of cancer patients, and growing adoption of companion diagnostics. Major trends in the forecast period include next-generation sequencing (NGS), integration with other omics, genomic technological advancements, product innovations, and advanced healthcare services.
Get Your Free Sample of The Global Genomic Biomarkers Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19485&type=smp
Which Market drivers have played a significant role in driving the genomic biomarkers market?
The increasing demand for personalized medicine is expected to propel the growth of the genomic biomarkers market going forward. Personalized medicine, also known as precision medicine, is a medical approach that tailors healthcare decisions and treatments to the individual characteristics of each patient, primarily based on their genetic and genomic information. The increasing demand for personalized medicine is due to several factors, such as the growing emphasis on patient-centered care, genetic sequencing and analysis advances, a patient-centric approach, and the use of EHRs to store and analyze patient data. Genomic biomarkers play a crucial role in personalized medicine by enabling healthcare providers to tailor medical treatments to an individual’s unique genetic makeup. This approach, also known as precision medicine, aims to optimize the effectiveness of treatments and minimize side effects by considering the genetic differences between individuals. For instance, in 2022, according to the Personalized Medicine Coalition, a US-based professional membership organization, 12 new customized medications were approved in 2022, accounting for around 34% of all newly approved treatments and a 34% increase over prior years. Therefore, the increasing demand for personalized medicine drives the growth of the genomic biomarkers market.
What are the key segments within the genomic biomarkers market?
The genomic biomarkersmarket covered in this report is segmented –
1) By Type: Predictive Biomarkers, Prognostic Biomarkers
2) By Disease Indication: Oncology, Cardiovascular Diseases, Neurological Diseases, Renal Disorders, Other Disease Indications
3) By Validation: Analytical Validation, Clinical Validation, Clinical Utility
4) By End-User: Hospitals, Diagnostic Centers, Other End User
Subsegments:
1) By Predictive Biomarkers: Drug Response Biomarkers, Companion Diagnostics Biomarkers, Pharmacodynamic Biomarkers, Predictive Genetic Markers for Disease Susceptibility
2) By Prognostic Biomarkers: Cancer Prognostic Biomarkers, Cardiovascular Disease Prognostic Biomarkers, Neurodegenerative Disease Prognostic Biomarkers, Infectious Disease Prognostic Biomarkers
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/genomic-biomarkers-global-market-report
Which key players are shaping the genomic biomarkers market?
Major companies operating in the genomic biomarkers market are Thermo Fisher Scientific Inc., Roche Diagnostics International Ltd., Illumina Inc., PerkinElmer Inc., Almac Group, Azenta Inc., Novogene Corporation, Oxford Nanopore Technologies Ltd., Celerion, Quanterix Corporation, Bio-Rad Laboratories Inc., NantHealth Inc., Centogene N.V., Sophia Genetics SA, Envisagenics, Deep Genomics, Creative Diagnostics, Macrogen Inc., Guardant Health Inc., Sema4
Which transformative trends will shape the genomic biomarkers market landscape?
Major companies operating in the genomic biomarkers market are focused on developing innovative products, such as lung reagents, to enhance the detection of specific genetic mutations in lung cancer, improve diagnostic accuracy, and facilitate personalized treatment approaches by leveraging advanced genomic technologies. Lung reagents refer to specialized chemical or biological substances used in diagnostic tests, research, or medical procedures related to the lungs helping in precision medicine by guiding treatment choices based on the specific genetic profile of the cancer. For instance, in December 2023, Biofidelity, a UK-based company specializing in developing advanced genomic assays and precision diagnostics, launched ASPYRE-Lung reagents. The ASPYRE-Lung reagents are designed to identify key genetic mutations and alterations in lung cancer, which are critical for guiding targeted therapies and personalized treatment strategies.
How do regional factors impact the genomic biomarkers market, and which region is the largest contributor?
North America was the largest region in the genomic biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genomic biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Genomic Biomarkers Market Report 2025 Offer?
The genomic biomarkers market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Genomic biomarkers are specific sequences or variations in DNA or RNA that provide information about a biological process, condition, or response to a particular treatment. These biomarkers are used in precision medicine to predict disease risk, diagnose conditions, monitor disease progression, or guide treatment decisions. Genomic biomarkers are crucial for personalized medicine, allowing healthcare providers to tailor treatments based on an individual’s genetic makeup, improving the effectiveness of therapies, and reducing the likelihood of adverse effects.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19485
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
